Published in Diabetes on April 14, 2010
Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol (2011) 2.71
A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int (2011) 2.30
Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol (2011) 2.06
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes (2010) 1.95
MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem (2011) 1.70
Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol (2012) 1.70
Diabetes complications: the microRNA perspective. Diabetes (2011) 1.60
microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am J Physiol Renal Physiol (2011) 1.50
Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens (2012) 1.46
miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer (2011) 1.44
Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res (2011) 1.43
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J Hematol Oncol (2014) 1.39
TGF-β/Smad signaling in renal fibrosis. Front Physiol (2015) 1.36
Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One (2012) 1.34
Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res (2010) 1.26
Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol (2013) 1.25
Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci (2011) 1.25
Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol (2011) 1.24
The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res (2013) 1.22
Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy. Diabetes (2011) 1.22
MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene (2013) 1.20
TGF-β: the master regulator of fibrosis. Nat Rev Nephrol (2016) 1.19
Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes (2013) 1.15
Role of MicroRNAs in Fibrosis. Open Rheumatol J (2012) 1.14
Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma. Oncogene (2014) 1.13
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med (2013) 1.08
Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl) (2012) 1.06
Systems biology of kidney diseases. Kidney Int (2011) 1.05
MicroRNAs and diabetic complications. J Cardiovasc Transl Res (2012) 1.04
Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS One (2013) 0.99
MicroRNAs in renal fibrosis. Front Physiol (2015) 0.98
miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol (2012) 0.98
MicroRNAs and the glomerulus. Exp Cell Res (2012) 0.97
TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal (2013) 0.97
Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. J Am Soc Nephrol (2013) 0.96
TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One (2012) 0.94
Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction? Cells (2015) 0.94
MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci (2015) 0.92
Connective tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue Repair (2012) 0.91
The role of microRNAs in diabetic nephropathy. J Diabetes Res (2014) 0.91
The genetics of diabetic nephropathy. Genes (Basel) (2013) 0.90
The Role of miRNAs as Key Regulators in the Neoplastic Microenvironment. Mol Biol Int (2011) 0.90
MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy. Semin Nephrol (2012) 0.90
MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis (2013) 0.90
Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer. Inflamm Res (2013) 0.89
MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis. Lab Invest (2015) 0.89
A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition. PLoS One (2011) 0.88
Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clin Epigenetics (2015) 0.88
miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol (2011) 0.88
Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics. Front Genet (2011) 0.88
Changes in the gene expression programs of renal mesangial cells during diabetic nephropathy. BMC Nephrol (2012) 0.87
MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. Exp Mol Med (2013) 0.87
Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures. Gene (2012) 0.87
The regulation and function of microRNAs in kidney diseases. IUBMB Life (2013) 0.87
Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses (2013) 0.86
Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes. Diabetes (2015) 0.86
From cellular senescence to age-associated diseases: the miRNA connection. Longev Healthspan (2012) 0.85
Translational study of microRNAs and its application in kidney disease and hypertension research. Clin Sci (Lond) (2012) 0.85
A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun (2016) 0.84
Rho kinase inhibition in diabetic kidney disease. Br J Clin Pharmacol (2013) 0.84
Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases. Am J Physiol Renal Physiol (2015) 0.83
miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47. Oncotarget (2015) 0.82
Role of regulatory micro RNAs in type 2 diabetes mellitus-related inflammation. Nucleic Acid Ther (2012) 0.81
miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy. J Diabetes Res (2016) 0.81
microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med (2014) 0.80
Involvement of YAP, TAZ and HSP90 in contact guidance and intercellular junction formation in corneal epithelial cells. PLoS One (2014) 0.79
MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy. Curr Diab Rep (2016) 0.79
Involvement of renal corpuscle microRNA expression on epithelial-to-mesenchymal transition in maternal low protein diet in adult programmed rats. PLoS One (2013) 0.79
Molecular signaling cascade of miRNAs in causing Diabetes Nephropathy. Bioinformation (2013) 0.78
Early detection of diabetic kidney disease: Present limitations and future perspectives. World J Diabetes (2016) 0.78
MicroRNA in situ hybridization for formalin fixed kidney tissues. J Vis Exp (2013) 0.77
The transcriptome of nitrofen-induced pulmonary hypoplasia in the rat model of congenital diaphragmatic hernia. Pediatr Res (2015) 0.76
Genetics and Epigenetics of Diabetic Nephropathy. Kidney Dis (Basel) (2015) 0.76
Urinary Exosomal microRNA-451-5p Is a Potential Early Biomarker of Diabetic Nephropathy in Rats. PLoS One (2016) 0.76
The coordinated roles of miR-26a and miR-30c in regulating TGFβ1-induced epithelial-to-mesenchymal transition in diabetic nephropathy. Sci Rep (2016) 0.75
p53 activates miR-192-5p to mediate vancomycin induced AKI. Sci Rep (2016) 0.75
MiR542-3p Regulates the Epithelial-Mesenchymal Transition by Directly Targeting BMP7 in NRK52e. Int J Mol Sci (2015) 0.75
The Expression of miR-192 and Its Significance in Diabetic Nephropathy Patients with Different Urine Albumin Creatinine Ratio. J Diabetes Res (2016) 0.75
Epigenetic Regulations in Diabetic Nephropathy. J Diabetes Res (2017) 0.75
The Effect of Regular Moderate Exercise on miRNA-192 Expression Changes in Kidney of Streptozotocin-Induced Diabetic Male Rats. Adv Pharm Bull (2015) 0.75
Differential expression of microRNAs in retinal vasculopathy caused by selective Müller cell disruption. Sci Rep (2016) 0.75
From Inflammation to Current and Alternative Therapies Involved in Wound Healing. Int J Inflam (2017) 0.75
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest (2003) 12.56
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol (2002) 10.59
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08
The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell (2001) 10.02
A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res (2008) 7.45
A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol (2002) 6.48
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res (2007) 4.65
Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol (2009) 4.32
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res (2008) 3.58
Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res (2004) 3.11
Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res (2008) 2.86
miR-200b mediates post-transcriptional repression of ZFHX1B. RNA (2007) 2.67
Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol (2010) 2.45
Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol (2008) 2.35
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest (2001) 2.20
Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology (2008) 2.07
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol (2006) 1.88
beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene (2004) 1.79
Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol Biol Cell (2007) 1.61
Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens (2009) 1.59
Tubular epithelial cell dedifferentiation is driven by the helix-loop-helix transcriptional inhibitor Id1. J Am Soc Nephrol (2007) 1.56
The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs (2007) 1.46
Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest (2009) 1.41
Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. Am J Physiol (1998) 1.28
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol (2004) 1.23
Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol (2004) 1.15
Role of ornithine decarboxylase for proliferation of mesangial cells in culture. Kidney Int (1991) 0.82
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res (2008) 7.45
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Insulin levels in insulin resistance: phantom of the metabolic opera? Med J Aust (2006) 5.33
MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle (2008) 4.81
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes (2008) 4.13
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Mechanisms of diabetic complications. Physiol Rev (2013) 3.41
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Experimental strategies for microRNA target identification. Nucleic Acids Res (2011) 3.00
Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 3.00
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J (2005) 2.66
Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care (2008) 2.66
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell (2002) 2.61
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes (2007) 2.51
An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell (2011) 2.49
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes (2009) 2.34
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension (2003) 2.10
TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem (2011) 2.06
Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol (2011) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
IsomiRs--the overlooked repertoire in the dynamic microRNAome. Trends Genet (2012) 2.00
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes (2010) 1.95
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 1.95
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol (2006) 1.88
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res (2012) 1.78
Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation (2007) 1.74
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens (2003) 1.70
The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust (2006) 1.68
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes (2004) 1.67
Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int (2011) 1.63
Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem (2005) 1.62
Slow, medium, or fast re-warming following post-traumatic hypothermia therapy? An ultrastructural perspective. J Neurotrauma (2005) 1.60
The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest (2011) 1.59
Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 1.59
Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol (2004) 1.58
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int (2010) 1.57
Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol (2009) 1.57
Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant (2013) 1.55
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 1.51
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol (2007) 1.49
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag (2008) 1.49
UKPDS and the legacy effect. N Engl J Med (2008) 1.49
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) (2012) 1.49
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol (2002) 1.46
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens (2002) 1.45
Assessing IRES activity in the HIF-1alpha and other cellular 5' UTRs. RNA (2006) 1.45
Change of HbA1c reporting to the new SI units. Med J Aust (2011) 1.44
The microRNA-200 family regulates epithelial to mesenchymal transition. ScientificWorldJournal (2008) 1.44
The role of EMT in renal fibrosis. Cell Tissue Res (2011) 1.43
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. Hypertension (2012) 1.43
Oral hypoglycaemics - a review of the evidence. Aust Fam Physician (2010) 1.43
Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care (2013) 1.40
Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 1.40
ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab (2004) 1.40
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens (2005) 1.40
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation (2004) 1.38
ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes (2008) 1.36
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes (2002) 1.36
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol (2005) 1.35
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J (2003) 1.33
Regulated post-transcriptional RNA cleavage diversifies the eukaryotic transcriptome. Genome Res (2010) 1.32
Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol (2003) 1.32
Human PABP binds AU-rich RNA via RNA-binding domains 3 and 4. Eur J Biochem (2004) 1.31
Connective tissue growth factor inhibits adipocyte differentiation. Am J Physiol Cell Physiol (2008) 1.30
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest (2012) 1.29
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation. Bioinformatics (2010) 1.28
Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol (2004) 1.28
Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol (2010) 1.28